Joseph Cooney
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Joseph Cooney has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Andrew Poullis
St George's University Hospitals NHS Foundation Trust London UK
2 shared publicationsBenjamin Shandro
ASt George's University Hospitals NHS Foundation Trust, London, UK
1 shared publication- Gauri Godbole
Gastrointestinal Bacteria Reference Unit, UK Health Security Agency, London, UK
1 shared publication Khizar Rafique
DSt George's University Hospitals NHS Foundation Trust, London, UK
1 shared publicationLulia Al-Hillawi
ASt George's University Hospitals NHS Foundation Trust, London, UK
1 shared publication- Peter L. Chiodini
Department of Clinical Parasitology, Hospital for Tropical Diseases, London, UK
1 shared publication
Latest Publications
- Open Access
- 7 October 2024
- Published by BMJ in Frontline Gastroenterology
- Vol. 16 (1) , 37-50
Recent advances in the diagnosis and management of amoebiasis
With increasing international travel and migration, tropical and infectious diseases once largely confined to specialist institutes now present more widely. Amoebiasis is a potentially dangerous example since it may closely mimic the presentation of inflammatory bowel disease. Misdiagnosis and treatment with immunosuppressants can result in fulminant amoebiasis and death. This review considers the epidemiology, pathogenesis, clinical features, diagnosis and treatment of intestinal and extraintestinal amoebiasis. It is written primarily for gastroenterologists, surgeons and acute physicians.
- 7 October 2024
- Published by BMJ in Frontline Gastroenterology
- Vol. 16 (1) , 37-50
Open AccessRecent advances in the diagnosis and management of amoebiasis
With increasing international travel and migration, tropical and infectious diseases once largely confined to specialist institutes now present more widely. Amoebiasis is a potentially dangerous example since it may closely mimic the presentation of inflammatory bowel disease. Misdiagnosis and treatment with immunosuppressants can result in fulminant amoebiasis and death. This review considers the epidemiology, pathogenesis, clinical features, diagnosis and treatment of intestinal and extraintestinal amoebiasis. It is written primarily for gastroenterologists, surgeons and acute physicians.
- 11 June 2022
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 34 (9) , e14420
Post‐COVID‐19 irritable bowel syndrome
- 11 June 2022
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 34 (9) , e14420
Post‐COVID‐19 irritable bowel syndrome
- Open Access
- 1 February 2022
- Published by Elsevier in Clinical Medicine
- Vol. 22 (2) , 181-183
COVID-19 infection causing residual gastrointestinal symptoms – a single UK centre case series
Although COVID-19 was first recognised as an acute respiratory illness, extra-pulmonary manifestations are increasingly being recognised. Acute gastrointestinal side effects have been well reported with COVID-19 infection and are estimated to affect around 17% of patients. With COVID-19 still being a relatively new illness, the chronic gastrointestinal symptoms are less well characterised. Post-infectious irritable bowel syndrome (IBS) can occur following bacterial and viral infections, and with ACE-2 receptors being shown to be present in the gastrointestinal tract and SARS-Cov-2 RNA being present in stool, SARS-CoV-2 is now appreciated as an enteric pathogen. In our study, we survey acute and chronic gastrointestinal symptoms after COVID-19 infection. We have conducted one of the few UK studies on gastrointestinal symptoms, with the longest follow-up duration of 6 months. We have found that gastrointestinal symptoms are common at 6 months, affecting 43.8% of our patients. Further research is needed to explore whether this represents a new post-COVID-19 IBS, which has not previous been described in the literature, including its clinical course and response to any potential medical therapies.
- 1 February 2022
- Published by Elsevier in Clinical Medicine
- Vol. 22 (2) , 181-183
Open AccessCOVID-19 infection causing residual gastrointestinal symptoms – a single UK centre case series
Although COVID-19 was first recognised as an acute respiratory illness, extra-pulmonary manifestations are increasingly being recognised. Acute gastrointestinal side effects have been well reported with COVID-19 infection and are estimated to affect around 17% of patients. With COVID-19 still being a relatively new illness, the chronic gastrointestinal symptoms are less well characterised. Post-infectious irritable bowel syndrome (IBS) can occur following bacterial and viral infections, and with ACE-2 receptors being shown to be present in the gastrointestinal tract and SARS-Cov-2 RNA being present in stool, SARS-CoV-2 is now appreciated as an enteric pathogen. In our study, we survey acute and chronic gastrointestinal symptoms after COVID-19 infection. We have conducted one of the few UK studies on gastrointestinal symptoms, with the longest follow-up duration of 6 months. We have found that gastrointestinal symptoms are common at 6 months, affecting 43.8% of our patients. Further research is needed to explore whether this represents a new post-COVID-19 IBS, which has not previous been described in the literature, including its clinical course and response to any potential medical therapies.